Prosecution Insights
Prosecution Insights
5 pending office actions • 4 art units • 4 examiners • 0 of 5 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (80%) |
| §102 only | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRAN, SUSAN T | 2 | 62.8% | +36.0% |
| KRISHNAN, GANAPATHY | 1 | 52.2% | +0.0% |
| BURKETT, DANIEL JOHN | 1 | 65.4% | +24.5% |
| CREWS, JARET JAMES | 1 | 44.3% | +71.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18042485 | COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL | BURKETT, DANIEL JOHN | 132d overdue |
| 18001635 | Dispersible Tablet Formulations Comprising Dolutegravir | TRAN, SUSAN T | 104d overdue |
| 18001634 | Formulations | TRAN, SUSAN T | 104d overdue |
| 17911712 | Compounds Useful in HIV Therapy | CREWS, JARET JAMES | 5d |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| 1693 | 1 |
| 1624 | 1 |
| 1691 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547001 | Compounds Useful in HIV Treatment | KRISHNAN, GANAPATHY | 1693 | §103 | Non-Final OA | 60d overdue | Pending | Aug 18, 2023 |
| 18042485 | COMBINATION OF CABOTEGRAVIR AND LEVONORGESTREL | BURKETT, DANIEL JOHN | 1624 | §103 | Non-Final OA | 132d overdue | Pending | Feb 22, 2023 |
| 18001635 | Dispersible Tablet Formulations Comprising Dolutegravir | TRAN, SUSAN T | 1615 | §102 | Final Rejection | 104d overdue | Pending | Dec 13, 2022 |
| 18001634 | Formulations | TRAN, SUSAN T | 1615 | §103 | Final Rejection | 104d overdue | Pending | Dec 13, 2022 |
| 17911712 | Compounds Useful in HIV Therapy | CREWS, JARET JAMES | 1691 | §103 | Final Rejection | 5d | Pending | Sep 15, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial